Animation of inflammatory substances being released at a cell’s surface

Animation of inflammatory substances being released at a cell’s surface

Animation of inflammatory substances being released at a cell’s surface

Our Science

We chase the miracles of science, working across disciplines to solve problems, take smart risks, and discover the extraordinary.

We’re determined to find answers for patients, and to develop medicines and vaccines with the potential to improve people’s lives. We focus, and we push our limits. Because when we work together we can grow, take smart risks, learn from failure, and discover the extraordinary. That’s how we turn the impossible into possible. And it’s how we will help make life better for people everywhere.

R&D Focus Areas

Vaccines

Immunology & Inflammation

Oncology

Rare Blood Disorders

Rare Diseases

Neurology

Our Pipeline

Our R&D pipeline reflects our emerging leadership in immunology1,2 and vaccines, and our fresh approach to oncology. Explore our clinical-stage investigational molecules to find out more.

Digital

Digital is at the heart of our ambition to transform the practice of medicine. 
Now is the time to embrace the next generation of healthcare. We take never-been-done ideas and turn them into reality. Every step of our value chain has undergone a deep digital transformation, and we’re just getting started. 

Voices From the Lab

Meet Nizar El-Murr

Meet Al Hassan Casse

Meet Bruno Gagliardo

Science & Innovation Stories

February 3, 2023

Personalized medicine for all: The future of cancer treatment

View all science stories

Science in Action

Work with us

Partner with us

Learn More About Our Clinical Research

Our Latest News

Ziyu Li inspects samples on a lab machine, wearing a white labcoat, purple gloves, and safety glasses.

November 13, 2024

How Immunoscience is Transforming Treatment for Type 1 Diabetes

References

  1. Hamers-Casterman C, et al. (1993) Nature 363:446-448; doi: 10.1038/363446a0
  2. Thibodeaux Q, et al. (2019) Hum Vaccines Immunother 15:2129-2139; DOI: 10.1080/21645515.2019.1582403

 

MAT-GLB-2200597 v2.0 09/2023